Q4 2024 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2025-02-18 · accession 0001892134-25-000001
$2.41B
Reported value
50
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $409.1M | 17.0% | 15,916,418 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $271.7M | 11.3% | 6,570,392 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $157.2M | 6.52% | 3,383,950 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $123.5M | 5.13% | 788,460 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $122.4M | 5.08% | 8,785,284 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $111.3M | 4.62% | 1,754,834 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $110.3M | 4.58% | 5,985,347 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $104.7M | 4.34% | 1,869,808 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $104.3M | 4.33% | 3,800,457 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $87.9M | 3.65% | 1,587,527 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $82.1M | 3.41% | 10,109,279 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $48.7M | 2.02% | 19,391,687 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $44.2M | 1.83% | 539,405 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $43.9M | 1.82% | 10,664,774 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $43.6M | 1.81% | 997,455 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $41.4M | 1.72% | 4,887,867 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $35.2M | 1.46% | 1,069,754 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $33.9M | 1.41% | 1,271,245 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $31.4M | 1.30% | 699,159 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $31.4M | 1.30% | 3,888,238 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $27.7M | 1.15% | 658,715 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $26.6M | 1.10% | 8,660,379 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $22.1M | 0.92% | 770,000 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $22.0M | 0.91% | 10,617,062 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $20.8M | 0.86% | 1,573,719 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $18.6M | 0.77% | 1,479,025 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $18.4M | 0.76% | 133,333 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $17.8M | 0.74% | 5,097,779 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $17.3M | 0.72% | 601,129 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $15.7M | 0.65% | 373,100 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $15.3M | 0.63% | 2,147,911 | Common | SOLE |
| 729139105 | PLRX | PLIANT THERAPEUTICS INC | $14.8M | 0.61% | 1,120,803 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $12.1M | 0.50% | 1,953,547 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $11.3M | 0.47% | 583,327 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $10.9M | 0.45% | 4,623,324 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $10.3M | 0.43% | 3,175,665 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $8.7M | 0.36% | 689,655 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $8.6M | 0.36% | 470,338 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $7.9M | 0.33% | 1,148,591 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $7.8M | 0.33% | 653,892 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $7.8M | 0.32% | 1,000,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $7.3M | 0.30% | 936,576 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $7.1M | 0.30% | 500,333 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $6.3M | 0.26% | 955,515 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $6.1M | 0.25% | 2,867,750 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $5.5M | 0.23% | 285,331 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $5.0M | 0.21% | 1,069,244 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $4.8M | 0.20% | 1,176,735 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $3.4M | 0.14% | 5,993,579 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $3.2M | 0.13% | 108,762 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.